PLIANT THERAPEUTICS, INC. (PLRX) Stock Profile — Insider Trades & Financials

Net Income-$23.6M

EPS$-2.05

Market Cap$84.2M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Bernard Coulie

CEO & Executive Director

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The companyâs lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of Î±vÃ8 and Î±vÃ1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Founded: 2015
Employees: 171
Headquarters: South San Francisco, California, United States

⚡

Core Efficiency

ROE?

-13.01%

ROA?

-10.47%

D/E Ratio?

0.24

📊

Profitability Ratios

Current Ratio?

12.00

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 4, 2026 (in 117 days)

Annual Report (10-K) — Based on filing pattern

Aug 4, 2026

Predicted10-K

Mar 11, 2026

10-KQ4 20256d after period end

Nov 6, 2025

10-QQ3 20255d after period end

Aug 7, 2025

10-QQ2 20256d after period end

May 8, 2025

10-QQ1 20257d after period end

Mar 3, 2025

10-KQ4 202410d after period end

Nov 7, 2024

10-QQ3 20246d after period end

Aug 7, 2024

10-QQ2 20246d after period end

May 6, 2024

10-QQ1 20245d after period end

Loading company sections...

PLIANT THERAPEUTICS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness